Neurology Medical News about Molecular Epigenetics

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Molecular epigenetics and genetics in neuro-oncology
Neurotherapeutics, 07/01/09

Nagarajan RP et al. - In a review of molecular epigenetics and genetics in neuro-oncology, it was concluded that although a majority of epigenetic alterations are independent of genetic alterations, there is interaction on specific genes, signaling pathways and within chromosomal domains. Next-generation sequencing technology is the method of choice for genomic and epigenome profiling, allowing more comprehensive understanding of genetic and epigenetic contributions to tumorigenesis in the brain.

Methods

Gliomas arise through genetic and epigenetic alterations of normal brain cells, although the exact cell of origin for each glioma subtype is unknown.
Alteration-induced changes in gene expression and protein function allow uncontrolled cell division, tumor expansion, and infiltration into surrounding normal brain parenchyma.
Genetic and epigenetic alterations are tumor subtype and tumor-grade specific.

Results

Particular alterations predict tumor aggressiveness, tumor response to therapy, and pt survival.
Genetic alterations include deletion, gain, amplification, mutation, and translocation, which result in oncogene activation and tumor suppressor gene inactivation, or in some instances the alterations may simply be a consequence of tumorigenesis.
Epigenetic alterations in brain tumors include CpG island hypermethylation associated with tumor suppressor gene silencing, gene-specific hypomethylation associated with aberrant gene activation, and genome-wide hypomethylation potentially leading to loss of imprinting, chromosomal instability, and cellular hyperproliferation.
Other epigenetic alterations, such as changes in position of histone variants and changes in histone modifications are also important in molecular pathology of brain tumors.
Given that histone deacetylases are targets for drugs that are already in clinical trial, surprisingly little is known about histone acetylation in primary brain tumors.

<< Previous
Convergence and divergence in a neural architecture for...

Next >>
Matrix metalloprotease regulation of neuropathic pain